Monte Rosa Therapeutics, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The company is a clinical-stage biotechnology company developing small-molecule molecular glue degraders (MGDs) using its QuEEN platform. It has no approved products and has generated no revenue from drug sales.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue from drug sales | None | None |
| Research and development expense | $85.1 million | $57.2 million |
| General and administrative expense | $27.3 million | $15.7 million |
| Total operating expenses | $112.4 million | $72.9 million |
| Net loss | $108.5 million | $74.0 million |
| Net loss per share, basic and diluted | $2.30 | $2.96 |
| Net cash used in operating activities | $92.5 million | $59.4 million |
At December 31, 2022, cash and cash equivalents were $54.9 million, marketable securities were $207.9 million, and restricted cash was $5.3 million. The filing reports $268.1 million in cash, cash equivalents, restricted cash and marketable securities; the financial-statement liquidity discussion cites $262.8 million for cash, cash equivalents and marketable securities, excluding restricted cash. Total assets were $342.4 million, total liabilities $71.0 million, and stockholders’ equity $271.4 million. No debt balance is reported.
Investing cash outflow was $219.2 million, primarily reflecting $384.4 million of marketable-security purchases, partly offset by $178.0 million of maturities, and $12.9 million of property and equipment purchases. Financing provided $20.5 million, principally from $19.7 million net proceeds from an at-the-market (ATM) stock offering. Operating cash use increased year over year. Profit margins are not meaningful because the company has no product revenue and reported operating losses.
Material changes versus 2021
- Net loss increased by $34.5 million; operating expenses rose $39.5 million. R&D expense increased $27.9 million and G&A expense increased $11.6 million, reflecting expanded research, headcount, facilities and public-company costs.
- Operating cash use increased by $33.1 million. Cash, cash equivalents and restricted cash fell to $60.2 million from $351.4 million, while the company shifted a substantial portion of its funds into marketable securities.
- The company began MRT-2359 clinical development, initiated a Phase 1/2 study in October 2022, and expanded preclinical programs. It sold 2.48 million shares through its ATM program in 2022 for $19.7 million net.
- Operating lease assets and liabilities were recognized following adoption of the lease accounting standard. Total operating lease liability was $47.0 million at year-end; undiscounted future lease payments were $74.3 million.
Outlook, developments and key risks
- Lead program: MRT-2359, an oral GSPT1-directed MGD, is in a Phase 1/2 trial for previously treated selected solid tumors, including MYC-driven lung cancers and high-grade neuroendocrine tumors. The filing expected initial Phase 1 clinical data—including safety, pharmacokinetics, pharmacodynamics and available efficacy—in the second half of 2023.
- The FDA granted MRT-2359 Fast Track designation in January 2023 for previously treated metastatic NSCLC with L-MYC or N-MYC expression. Fast Track is not approval and does not ensure a faster development or review process.
- CDK2, NEK7 and VAV1 programs were in lead optimization; management anticipated nominating multiple development candidates in 2023. Additional programs, including a sickle cell disease program, remained preclinical or at discovery stage.
- Management stated that existing cash and securities were expected to fund planned operations for at least 12 months from the financial-statement issuance date. Elsewhere, the filing estimated funding into 2025, based on assumptions and without additional collaboration funding. The company expects continuing losses and will need additional financing to advance development.
- Key risks include uncertain clinical efficacy and safety, the novel nature of the platform, regulatory and trial delays, competition, reliance on third-party manufacturers and CROs, limited patent maturity, and potential need for further capital and dilution. The company had no issued patents as of year-end; patent applications were early in prosecution.
- Potential obligations under the CRT/Institute of Cancer Research collaboration include milestone payments of up to $7.0 million for a first covered product and $3.5 million for each additional covered product, plus low-single-digit royalties if applicable.
- The company reported no material litigation. It reported effective disclosure controls and internal control over financial reporting as of year-end; previously disclosed material weaknesses were reported remediated. The auditor did not provide an internal-control attestation.
- Subsequent event: approximately 2% of total cash, cash equivalents and marketable securities was held at Silicon Valley Bank when it closed in March 2023; the company reported regaining full access to those funds on March 13, 2023.
Important facts for investors to verify
- Current cash runway and expected burn, including the difference between the filing’s “at least 12 months” and “into 2025” statements.
- MRT-2359 trial enrollment, dose escalation, safety, pharmacodynamic evidence and timing or availability of clinical results.
- Progress and candidate-selection milestones for CDK2, NEK7, VAV1 and other preclinical programs.
- Future ATM usage, share dilution, and whether additional financing or partnerships will be needed sooner than expected.
- Manufacturing and supply continuity, including exposure to external vendors, and the size and terms of future lease commitments.
- Patent application progress, scope and durability of protection, and any applicable collaboration milestones or royalties.